全球疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計疫苗市場將從 2025 年的 1,533 億美元成長到 2034 年的 2,295.9 億美元，2026 年至 2034 年的複合年成長率為 4.59%。

由於人們對疾病預防和公共衛生的日益關注，全球疫苗市場正經歷顯著成長。疫苗在保護人們感染疾病發揮著至關重要的作用，它能刺激免疫系統識別並對抗有害病原體。世界各國政府和衛生機構正在擴大免疫接種計劃，以改善公共衛生狀況。

多種因素正在推動疫苗市場成長。主要因素包括公眾健康意識的提高和政府對疫苗接種計畫的投入增加。此外，生物技術和疫苗研發技術的進步也使得更有效的新型疫苗得以研發。全球疫苗宣傳活動顯著提升了對免疫產品的需求。

隨著研究機構不斷研發針對新興感染疾病的疫苗，疫苗市場預計將持續成長。 mRNA和先進遞送系統等技術創新正在提高疫苗的效力和生產效率。在全球醫療衛生基礎設施持續投入的背景下，疫苗對於疾病預防和公共衛生保護仍將至關重要。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球疫苗市場：依疫苗類型分類

• 市場分析、洞察與預測
• 失活
• 減毒活病毒疫苗
• 類毒素
• 組合型
• 其他

第5章：全球疫苗市場：以價態分類

• 市場分析、洞察與預測
• 疫苗單價
• 多價疫苗

第6章 全球疫苗市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物
• 其他

第7章：全球疫苗市場：依適應症分類

• 市場分析、洞察與預測
• 流感
• 肝炎
• 脊髓灰質炎
• 病菌感染
• 肺炎鏈球菌感染
• DTP
• 輪狀病毒
• MMR
• 人類乳突病毒
• 其他

第8章 全球疫苗市場：依通路分類

• 市場分析、洞察與預測
• 向機構銷售
• 醫院藥房
• 零售藥房

第9章 全球疫苗市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AstraZeneca
  • GlaxoSmithKline Plc
  • Sanofi Pasteur SA
  • Pfizer Inc
  • Panacea Biotec
  • Merck & Co. Inc
  • Janssen Pharmaceutical Companies
  • Serum Institute Of India Pvt. Ltd
  • Emergent BioSolutions Inc
  • CSL Limited
  • Bavarian Nordic
  • IBSS Biomed SA
  • Novavax AB
  • Mitsubishi Tanabe Pharma Corporation

The Vaccine Market size is expected to reach USD 229.59 Billion in 2034 from USD 153.30 Billion (2025) growing at a CAGR of 4.59% during 2026-2034.

The global vaccine market has experienced substantial growth due to increasing focus on disease prevention and public health initiatives. Vaccines play a critical role in protecting populations from infectious diseases by stimulating the immune system to recognize and combat harmful pathogens. Governments and healthcare organizations worldwide have expanded immunization programs to improve public health outcomes.

Several factors are driving the growth of the vaccine market. Rising awareness about preventive healthcare and increasing government funding for vaccination programs are major contributors. Advances in biotechnology and vaccine development technologies have also enabled the creation of new and more effective vaccines. Global vaccination campaigns have significantly increased demand for immunization products.

Looking ahead, the vaccine market is expected to continue growing as research institutions develop vaccines for emerging diseases. Technological innovations such as mRNA and advanced delivery systems are improving vaccine effectiveness and production efficiency. With ongoing investments in global healthcare infrastructure, vaccines will remain essential for disease prevention and public health protection.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

• Inactivated
• Live Attenuated
• Toxoid
• Conjugate
• Others

By Valence

• Monovalent
• Multivalent

By Route of Administration

• Oral
• Injectable
• Others

By Indication

• Influenza
• Hepatitis
• Polio
• Meningococcal Disease
• Pneumococcal Disease
• DTP
• Rotavirus
• MMR
• Human Papilloma Virus
• Others

By Distribution Channel

• Institutional Sales
• Hospital Pharmacies
• Retail Pharmacies

COMPANIES PROFILED

• AstraZeneca, GlaxoSmithKline plc, Sanofi Pasteur SA, Pfizer Inc, Panacea Biotec, Merck Co Inc, Janssen Pharmaceutical Companies, Serum Institute of India Pvt Ltd, Emergent BioSolutions Inc, CSL Limited, Bavarian Nordic, IBSS Biomed SA, Novavax AB, Mitsubishi Tanabe Pharma Corporation
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VACCINE MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Vaccine Type
• 4.2. Inactivated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Live Attenuated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Toxoid Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.5. Conjugate Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL VACCINE MARKET: BY VALENCE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Valence
• 5.2. Monovalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Multivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL VACCINE MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL VACCINE MARKET: BY INDICATION 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast Indication
• 7.2. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.4. Polio Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.5. Meningococcal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.6. Pneumococcal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.7. DTP Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.8. Rotavirus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.9. MMR Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.10. Human Papilloma Virus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.11. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Institutional Sales Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.4. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.2.1 By Vaccine Type
  • 9.2.2 By Valence
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Indication
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.3.1 By Vaccine Type
  • 9.3.2 By Valence
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Indication
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.4.1 By Vaccine Type
  • 9.4.2 By Valence
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Indication
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.5.1 By Vaccine Type
  • 9.5.2 By Valence
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Indication
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.6.1 By Vaccine Type
  • 9.6.2 By Valence
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Indication
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL VACCINE INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 AstraZeneca
  • 11.2.2 GlaxoSmithKline Plc
  • 11.2.3 Sanofi Pasteur SA
  • 11.2.4 Pfizer Inc
  • 11.2.5 Panacea Biotec
  • 11.2.6 Merck & Co. Inc
  • 11.2.7 Janssen Pharmaceutical Companies
  • 11.2.8 Serum Institute Of India Pvt. Ltd
  • 11.2.9 Emergent BioSolutions Inc
  • 11.2.10 CSL Limited
  • 11.2.11 Bavarian Nordic
  • 11.2.12 IBSS Biomed S.A
  • 11.2.13 Novavax AB
  • 11.2.14 Mitsubishi Tanabe Pharma Corporation